7月8日 - ** 药物开发商科景生物COGT.O股价上涨5.4%，报9.85美元
** H.C. Wainwright将COGT的预测价格从12美元上调至22美元
** COGT周一表示，其药物贝珠司替尼（bezuclastinib）对肥大细胞增多症（一种血液疾病）患者症状的减轻具有统计学意义。
** Wainwright称贝珠单抗在NonAdvSM的获批概率从之前的60%提高到了95%。
** 券商称，2025年对COGN来说是具有里程碑意义的一年，这可能使其成为一个有吸引力的并购目标
** 截至上次收盘，该股今年累计上涨 19.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.